A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Exclusion Criteria

• •3. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
• •4. Subject has adequate bone marrow (independent of growth factor support per local laboratory reference range).
• •5. Subject has adequate coagulation, renal and hepatic function.
• •1. Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD), Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia (CLL), mantle cell leukemia (MCL), or small lymphocytic lymphoma (SLL).
• •2. Subject has undergone an allogeneic stem cell transplant.
• •3. Subject is receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV) (due to potential drug-drug interactions, as well as the potential for increased risk of opportunistic infections).
• •4. Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease within 6 months that in the opinion of the Investigator would adversely affect his/her participation in this study.
• •5. Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.